COMMUNIQUÉS West-GlobeNewswire

Biolojic Design Receives U.S. FDA Clearance of Investigational New Drug (IND) Application for BD200, the First Multibody to Enter Clinical Trials
12/11/2026
BD200 is a multibody drug conjugate, in which each arm of the antibody can alternatively bind to either Nectin-4 or Trop2, two validated oncology antigens that may be expressed on cancer cells Combined with a unique [...]
123Dentist CEO Jeff Leger and family establish fund at Dalhousie University’s Faculty of Dentistry to advance research into the connection between oral health and overall health
12/11/2026
The Leger Family Oral Health Research Fund will back research that deepens understanding of how oral health connects to overall health and chronic disease TORONTO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Jeff Leger, Chief [...]
Jeff Leger, président-directeur général de 123Dentiste, et sa famille créent un fonds à la Faculté de médecine dentaire de l’Université Dalhousie pour mieux comprendre le lien entre santé buccodentaire et santé globale
12/11/2026
Le Fonds de recherche en santé buccodentaire de la famille Leger soutiendra des travaux visant à mieux comprendre les liens entre la santé buccodentaire, la santé globale et les maladies chroniques TORONTO, 12 nov. 2026 [...]
Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update
12/11/2026
REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submission pathway in 1H 2027 TSHA-102 continues to be [...]
Altimmune Announces Third Quarter 2026 Financial Results and Business Update
12/11/2026
Global PERFORMA Phase 3 trial in MASH progressing as planned Positive RECLAIM Phase 2 data in AUD highlighted in a late-breaking oral presentation at AASLD The Liver Meeting® 2026 End-of-Phase 2 meeting with FDA for AUD [...]
Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16
12/11/2026
Company to report third quarter 2026 financial results and host conference call at 8:30 a.m. ET HOUSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology [...]
Immuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid Cancer
12/11/2026
- Company plans to evaluate atebimetinib in combination with chemotherapy in a Phase 2 clinical trial in patients with anaplastic thyroid cancer (ATC), a highly aggressive cancer with significant unmet need commonly [...]
Avicanna Reports Positive Adjusted EBITDA for Q3 2026 and Provides Corporate Update
12/11/2026
Adjusted EBITDA of $0.22 million, improves $1.01 million year-over-year, operating loss narrows by 80% Proprietary products reach 31% of MyMedi.ca sales, up from 19%; QUIX™ launches with 10 SKUs TORONTO, Nov. 12, 2026 ( [...]
Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
12/11/2026
‒ Recently announced acquisition of assets of Heron Therapeutics – ‒ Q3 2026 consolidated revenue of $54.5 million ‒ ‒ Q3 2026 net loss of $14.7 million ; Adjusted EBITDA of $3.1 million ‒ ‒ Company maintains FY 2026 [...]
Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients
12/11/2026
- Collaboration aligns with Immuneering’s expanding strategy to provide a broad population of cancer patients with a wide set of treatment options - - Represents Immuneering’s fourth agreement with a pharma partner - - [...]
Vor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise
12/11/2026
RemeGen’s expertise and next generation engineering expand Vor Bio’s leadership in the BAFF/APRIL field RC298 is a next generation, long-acting dual BAFF/APRIL inhibitor designed to combine high potency and extended [...]
MediPharm Labs Reports Q3 2026 Results with Second Consecutive Quarter of Positive Net Income and 18% Sequential Revenue Growth
12/11/2026
Net Income was positive for the second consecutive quarter, and Adjusted EBITDA 1 positive for its third consecutive quarter. Net Revenue of $11.8M increased 18% versus Q2 2026, with German revenue increasing 19% [...]
Dyadic’s C1-Produced RSV and Malaria Antibodies Advance into Animal Studies Following Positive Independent Evaluations
12/11/2026
Preclinical Studies Will Compare C1-Produced Antibodies to Their CHO-Produced Counterparts JUPITER, Fla., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), [...]
Ascendis Pharma Reports Third Quarter 2026 Financial Results
12/11/2026
Q3 2026 product revenue of €366 million (+89% Y/Y), comprising €291 million for YORVIPATH ® , €59 million for SKYTROFA ® , and €16 million for YUVIWEL ® Received positive CHMP and COMP opinions recommending EU marketing [...]
Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update
12/11/2026
GB-0895 is being evaluated in two Phase 3 severe asthma studies for dosing twice a year A single dose of GB-0895 produced sustained pharmacological activity for at least six months in COPD Zealand Pharma collaboration [...]
Altimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & Hepatology
12/11/2026
Significant reductions across non-invasive measures of liver fat, inflammation and fibrosis observed at 48 weeks of pemvidutide treatment, with generally favorable tolerability profile Publication of results provides [...]
NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury
12/11/2026
Breakthrough Therapy designation granted based on FDA’s review of safety and efficacy data from the chronic cohort of the Phase 1b/2a CONNECT SCI study Phase 3 RESTORE registrational study enrolling participants, with [...]
Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference
12/11/2026
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying [...]
Maple Report: More than half of Canadian patients and families report being left without adequate updates while waiting for care
12/11/2026
New national research reveals the hidden workload, uncertainty, and emotional toll experienced by patients and families in the countless hours between care. TORONTO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- A new report titled [...]

Pages